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Research on TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors has advanced tremendously over the past 17 years. 
Initial observations of TRAIL and TRAIL receptor-mediated tumor cell toxicity led to enthusiasm of exploiting this selective, malignant cell 
killing for cancer therapy. Further examination revealed aberrant TRAIL signaling in some cancer cells leading to protection from TRAIL-
mediated cell death. Mechanisms of TRAIL resistance often involve decreased expression or activity of initiator caspase-8, crucial for 
complete TRAIL signal transduction. Caspase-8 mutations, epigenetic silencing, decrease in stability, and incomplete activation have been 
reported. This article reviews the discovery of TRAIL and TRAIL receptors and subsequent studies that reveal how expression and function 
of caspase-8 are central to TRAIL-mediated cell death. This article is part of a Special Issue entitled “Apoptosis: Four Decades Later”.
Key Words: TRAIL, caspase-8, cell death, cancer, epigenetic silencing, ubiquitination.
INTRODUCTION
The discovery of TNF-related apoptosis-inducing 
ligand (TRAIL) in 1995 was the beginning of exciting 
research that is now approaching two decades [1]. 
TRAIL was identified as a member of the TNF family 
[2]. By 1998, five TRAIL receptors had been discovered 
and characterized. TRAIL-receptor 1 (DR4) and TRAIL-
receptor 2 (DR5) are pro-apoptotic TRAIL receptors ca-
pable of mediating cell death. TRAIL-receptor 3 (DcR1) 
and TRAIL-receptor 4 (DcR2) are decoy TRAIL receptors 
unable to induce cell death due to deficient intracellular 
signaling domain or truncated death domain, respec-
tively [3–7]. Osteoprotegerin (OPG), identified in 1998, 
is a soluble TRAIL decoy receptor shown to be important 
for osteoclast development [8]. 
TRAIL expression has been found in various types 
of human tissues. Endogenous TRAIL has both innate 
and adaptive immune system functions [9]. TRAIL 
plays a role in immunosurveillance and has been 
shown to kill malignant cells as wells as bacterial and 
viral infected cells [9]. TRAIL’s ability to cause toxicity 
in various cancer cells while leaving normal cells un-
harmed made it an exciting, potential cancer therapy. 
TRAIL-based therapies are currently being evaluated 
for clinical use. 
Cancer cell resistance to TRAIL-mediated cell 
death has been noted and resistance mechanisms 
have been investigated extensively. Mechanisms 
include but are not limited to aberrant TRAIL recep-
tor cell surface expression and presentation [10], 
TRAIL receptor glycosylation [11], recruitment of the 
functionally inactive caspase-8 homologue FLIP to the 
death-inducing signaling complex (DISC) [12, 13], 
decreased oncogene c-myc expression [14], and in-
creased anti-apoptotic Bcl-2 family member Mcl-1 ex-
pression [15]. These mechanisms are of importance 
and have provided insight into molecular determinants 
of TRAIL sensitivity. However, this review will focus 
on caspase regulation of TRAIL-induced cell death, 
specifically caspase-8. Initiator caspase-10 can 
be recruited to the DISC but cannot functionally sub-
stitute for caspase-8 in mediating cell death [16, 17]. 
Caspase-8 is the focal apical caspase for the TRAIL 
signaling pathway and this review will highlight the 
significance of caspase-8 expression and activity 
in TRAIL-induced apoptosis [18]. 
CASPASE-8
Caspase-8 is a 55 kDA cysteine protease. Cas-
pase-8 has 480 amino acids and contains two death 
effector domains and a catalytic protease domain [18]. 
Procaspase-8 is the inactive zymogen that requires 
activation for complete activity [18]. Caspase-8 re-
quires multiple steps for activation that include oligo-
merization and proteolysis cleavage [19]. Active cas-
pase-8 consists of a tetramer with two large and small 
subunits. The first cleavage of caspase-8 generates 
p43/41 intermediate fragments. Additional cleavage 
product are p26/24, p18 and p10 fragments [19]. 
Multiple caspase-8 isoforms have been described 
with caspase-8/a (55 kDa) and caspase-8/b (53 kDa) 
being the predominant isoforms expressed in cells and 
the characteristic caspase-8 doublet seen by western 
blotting [20]. A caspase-8 alternative splice variant, 
caspase-8L, has been identified and can protect 
against caspase-8-mediated cell death [21, 22].
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TRAIL SIGNALING
TRAIL signaling leads to cell death by utilizing both 
extrinsic and intrinsic pathways [19, 23]. The intrinsic 
pathway involves mitochondrial permeabilization and 
release of pro-apoptotic factors that lead to caspase 
cascade activation. TRAIL ligation to DR4 or DR5 causes 
receptor clustering and trimerization. Intracellular 
adaptor protein FADD is recruited to the death domain 
of the TRAIL receptor. Initiator caspase-8 is recruited 
to the complex collectively known as the death-inducing 
signaling complex (DISC) and interacts with FADD 
through their death effector domains [24]. DISC acti-
vation of caspase-8 leads to caspase cascade activa-
tion where downstream effector caspase-3 becomes 
activated and cleaves protein targets that culminate 
in cell death. Additionally, caspase-8 can cleave the 
Bcl-2 related protein Bid. Truncated Bid (tBid) translo-
cates into the mitochondria and causes release of cy-
tochrome c and the formation of the Apaf-1containing 
apoptosome and subsequent caspase-9 activation 
[24]. Activated caspase-9 can then activate effector 
caspase-3 resulting in cell death (Fig. 1).
Fig. 1. Extrinsic and intrinsic TRAIL signaling pathways. TRAIL 
ligation to a pro-apoptotic TRAIL receptor causes receptor 
trimerization and activation of initiator caspase-8 and effector 
caspase-3, leading to cell death. Alternatively, caspase-8 can 
cleave Bid. Truncated Bid triggers the release of cytochrome 
c and formation of the apoptosome. The apoptosome activates 
caspase-9 resulting in activation of caspase-3 and cell death
TRAIL RESISTANCE
Caspase-8 mutations
Caspase-8 mutations in malignant cells were first 
noted in squamous cell carcinoma of the oral cavi-
ty. A point mutation that altered the stop codon and 
increased the size of the encoded protein was found 
in patient-derived cells but not in autologous PHA-treated 
blood lymphocytes [25]. These cancer cells were also 
less sensitive to apoptosis induced by caspase-8 over 
expression, suggesting that the mutation reduced cas-
pase-8 activity. Caspase-8 mutations have also been 
identified in hepatocellular and gastric carcinomas with 
defective apoptosis activities observed in mutants [26, 
27]. Five caspase-8 mutations were identified in inva-
sive colorectal carcinomas that include three missense 
mutations, one frame-shift mutation, and one nonsense 
mutation [28]. 293T cells transfected with mutant cas-
pase-8 expression vectors showed decreased apoptosis 
after DR5 overexpression. Collectively theses studies 
highlight that caspase-8 mutations are present in a va-
riety of malignancies and these mutations inactivate the 
cysteine protease and lead to reduced spontaneous and 
receptor mediated-cell death.
Decreased caspase-8 expression and epige-
netic silencing
The previously mentioned studies detected cas-
pase-8 mutations in malignant cells yet these mutations 
were not associated with loss of caspase-8 expres-
sion. Dual observations of caspase-8 mutation and 
undetectable caspase-8 expression have been noted 
in HOC313 head and neck carcinoma cells [29]. Che-
moresistance to the anti-cancer drug cisplatin was also 
observed in HOC313 cells. Loss of caspase-8 expression 
has been described in childhood neuroblastomas and 
medulloblastomas insensitive to TRAIL-induced cell death. 
Treatment with DNA methyltransferase inhibitor 5’Aza-
deoxycytidine (5-Aza) increased caspase-8 mRNA and 
protein expression in both TRAIL-resistant neuroblastoma 
[30, 31] and medulloblastoma [32, 33] cancer cells, sug-
gesting that epigenetic silencing was responsible for the 
downregulation of caspase-8. Increased caspase-8 ex-
pression was associated with enhanced TRAIL-medi-
ated cell death. Further investigation of TRAIL-resistant 
neuroblastoma revealed that invasive neuroblastoma 
cells have increased TRAIL resistance and decreased 
caspase-8 mRNA and protein compared to non-invasive 
neuroblastoma cell lines [31]. Treatment of invasive neu-
roblastoma cells with DNA methyltransferase inhibitor 
Azacytidine, increased caspase-8 protein expression and 
increased cell death after co-treatment of Azacytidine and 
TRAIL. Silencing of caspase-8 expression by DNA meth-
ylation has also been noted in small cell lung carcinoma 
[34]. 5-Aza treatment also increased caspase-8 protein 
expression and improved TRAIL sensitivity. 
DNA hypermethylation is not the only epigenetic 
mechanism found to be responsible for decreased 
caspase-8 expression. Histone hypoacetylation has 
also been found to result in caspase-8 downregula-
tion. Medulloblastoma cell treatment with histone 
deacetylase (HDAC) inhibitors valproic acid (VA) 
and suberoylanilide hydroxamic acid (SAHA) also 
increased caspase-8 expression [35]. 
These reports underline caspase-8 epigenetic 
silencing by DNA methylation as a means for malig-
nant cancer cells to decrease caspase-8 expression 
and avoid TRAIL-induced cell death. TRAIL resistance 
noted by epigenetic silencing of caspase-8, em-
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phasizes the requirement of caspase-8 expression 
for complete TRAIL signaling. Modulation of cas-
pase-8 has been studied to define treatments that 
increase caspase-8 expression and thus enhance 
TRAIL-mediated cell death. 
Cytokine Interferon gamma (IFNγ) was previously 
shown to increase TRAIL sensitivity in a dose-depen-
dent manner in Ewing sarcoma, neuroblastoma, and 
medulloblastoma cells [36]. Further examination 
revealed increased caspase-8 expression, but not 
effector caspase-3 expression, after treatment with 
IFNγ. Co-treatment with TRAIL and IFNγ resulted 
in markedly enhanced caspase-mediated cell death. 
IFNγ mediated caspase-upregulation was found 
to be Stat1 dependent [36]. IFNγ treatment did not 
change the methylation status of caspase-8 [36].
Decreased caspase-8 stability
Decreased caspase-8 stability and accele rated deg-
radation has been reported in TRAIL resistant DLD1 colon 
cancer cells [37]. Restoration of caspase-8 expression 
in resistant DLD1 cells resulted in increased TRAIL-
induced apoptosis. Caspase-8-and caspase-10-as-
sociated RING proteins, CARP1 and CARP2 mRNA 
were upregulated in TRAIL-resistant colon cancer cells 
compared to TRAIL-sensitive parental cells. CARP1 and 
CARP2 aid in ubiquitin-mediated proteolysis of death 
effector domain containing caspases [38].
Proteasome inhibitor stabilization of caspase-8 re-
mains controversial. Caspase-8 stabilization after pro-
teasome inhibition has been noted in some cancer 
cells [39]. Conversely, caspase-8 expression was 
unchanged in ovarian carcinoma cells after treatment 
with the proteasome inhibitor MG132 [40]. These dif-
ferences may be cell type dependent. Additionally, 
autophagic lysosomal caspase-8 degradation has also 
been described [41].
Caspase-8 ubiquitination
Several caspase-8 post-translational modifications 
have been identified including caspase-8 phosphory-
lation and ubiquitination. Caspase-8 phosphorylation 
has been noted on various residues (Thr263, Tyr380, 
Tyr397, Tyr645) [42–47]. Caspase-8 phosphoryla-
tion is reported to inhibit caspase-8 activity. Yet, cas-
pase-8 phosphorylation status in TRAIL-resistant can-
cer cells has not been thoroughly explored. In 2009, 
Jin and colleagues revealed that TRAIL treatment 
induces caspase-8 ubiquitination in TRAIL-sensitive 
H460 lung cancer cells [48]. The E3 ligase CUL3 was 
shown to interact with caspase-8 and was associated 
with the DISC after TRAIL treatment. Knockdown 
of CUL3 decreased caspase-8 ubiquitination and 
activity and limited TRAIL-mediated apoptosis. TRAIL 
treatment caused both K48 and K63 polyubiquitina-
tion chains to be added to caspase-8 [48]. Additio-
nally, Jin et al. reported that ubiquitin binding protein 
p62 promoted TRAIL-induced caspase-8 aggregation. 
siRNA knockdown of p62 diminished TRAIL-induced 
caspase-8 ubiquitination and activity. No cas-
pase-8 ubiquitination and processing was observed 
in two TRAIL-resistant cell lines, HeLa and ADR-RES 
[48]. This study highlights post-translational ubiqui-
tination of caspase-8 for complete TRAIL sensitivity.
A recent report by Bellail and colleagues examined 
ubiquitin enzymes A20 and CUL3 in TRAIL-sensitive 
and TRAIL-resistant glioblastoma cell lines. Unlike 
H460 lung cancer cells, TRAIL-sensitive glioblas-
toma cells had no detectable caspase-8 ubiquitination 
or CUL3 in the DISC after TRAIL treatment [49]. Little 
A20 expression was detected in TRAIL-sensitive glio-
blastoma cells. Introduction of A20 expression plasmids 
reversed TRAIL sensitivity. The A20 zinc finger domain, 
that confers E3 ligase capability, was found to be neces-
sary for A20-mediated TRAIL resistance [49]. Further 
investigation found that A20 attaches K63 polyubiquitin 
chains to RIP1 and these polyubiquitin chains interact 
with caspase-8. An in vitro caspase-8 cleavage assay 
revealed that K63 polyubiquitin chains inhibit cas-
pase-8 processing [49]. These stu dies show how in two 
different malignant cell types, direct caspase-8 ubiqui-
tination or association with a polyubi quitinated protein 
can enhance or inhibit TRAIL-mediated cell death, 
respectively. In TRAIL-sensitive H460 lung cancer cells, 
caspase-8 is ubiquitinated and undergoes aggrega-
tion required for complete caspase-8 activation and 
activation of downstream caspase cascade (Fig. 2). 
In TRAIL-resistant glioblastomas, caspase-8 interacts 
with A20-induced K63 polyubiquitin chains attached 
to RIP1 that hinder caspase-8 activation and process-
ing (Fig. 3). 
Fig. 2. Schematic of TRAIL susceptibility after caspase-8 poly-
ubiquitination. (Left; Example TRAIL-sensitive H460 cells) TRAIL 
ligation to a pro-apoptotic TRAIL receptor causes E3 Ligase 
CUL3 to polyubiquitinate caspase-8. Ubiquitinated caspase-8 can 
properly aggregate and complete caspase-8 and caspase-3 ac-
tivation leads to cell death. (Right; Example TRAIL-resistant HeLa 
cells) Caspase-8 that is not ubiquitinated cannot be fully activated 
which leads to failure to activate caspase-3 and cause cell death 
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Fig. 3. Schematic of TRAIL resistance after caspase-8 associa-
tion with polyubiquitinated RIP1. (Left; Example of TRAIL-sensitive 
glioblastoma cells LN71) TRAIL ligation causes activation of initiator 
caspase-8 and effector caspase-3, leading to cell death. (Right; 
Example of TRAIL-resistant glioblastoma cells LN443) The E3 ligase 
zinc finger domain of A20 polyubiquitinates RIP1. Caspase-8 inter-
acts with polyubiquitinated RIP1. Polyubiquitinated RIP1 inhibits 
caspase-8 processing and subsequent signaling of apoptosis
CONCLUDING REMARKS
TRAIL susceptibility in malignant cells is the founda-
tion for various TRAIL-based therapies currently being 
explored for translational use. Yet, not all cancer cells 
are sensitive to TRAIL-induced cell death. It is not hard 
to imagine that cancer cells have acquired mechanism(s) 
that escape TRAIL immunosurveillance and inhibit cell 
death. Abnormalities in expression and activation status 
of the upstream executioner caspase-8 are detailed 
in this review. Restoration of caspase-8 expression 
or activity sensitizes various TRAIL-resistant cancer cells. 
Future studies focusing on modulation of caspase-8 ex-
pression and upregulation will further contribute to the 
scientific knowledge of molecular determinants that 
confer TRAIL resistance and will likely aid in the efficacy 
of TRAIL-based therapies.
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